Who are A. CNS 7056's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): BENZHYDROCODONE, NALBUPHINE HYDROCHLORIDE, Standard Opioid, standard opioid prescribing, Individualized oral morphine, Motrin and narcotic.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/a-cns-7056.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

A. CNS 7056 — Competitive Intelligence Brief

A. CNS 7056 (A. CNS 7056) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: opioid receptor antagonist. Area: Pain.

phase 2 opioid receptor antagonist kappa opioid receptor Pain Small molecule Live · refreshed every 30 min

Target snapshot

A. CNS 7056 (A. CNS 7056) — Paion UK Ltd.. CNS 7056 is a kappa opioid receptor antagonist.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
A. CNS 7056 TARGET	A. CNS 7056	Paion UK Ltd.	phase 2	opioid receptor antagonist	kappa opioid receptor
BENZHYDROCODONE	BENZHYDROCODONE		marketed	Opioid analgesic combination; full mu-opioid agonist with non-opioid analgesic	Mu-opioid receptors (primary); delta and kappa opioid receptors (secondary); central nervous system pain pathways	2018-01-01
NALBUPHINE HYDROCHLORIDE	NALBUPHINE HYDROCHLORIDE		marketed		kappa opioid receptors, mu opioid receptors	1979-01-01
Standard Opioid	Standard Opioid	Prisma Health-Upstate	marketed	Opioid analgesic	Mu opioid receptor (primary); delta and kappa opioid receptors (secondary)
standard opioid prescribing	standard opioid prescribing	Walter Reed National Military Medical Center	marketed	Opioid analgesic	Mu opioid receptor, delta opioid receptor, kappa opioid receptor
Individualized oral morphine	Individualized oral morphine	Children's Hospital of Fudan University	marketed	Opioid analgesic	Mu opioid receptor (primary), delta opioid receptor, kappa opioid receptor
Motrin and narcotic	Motrin and narcotic	Cape Fear Valley Health System	marketed	NSAID + opioid analgesic combination	COX-1/COX-2 (ibuprofen); mu, delta, and kappa opioid receptors (narcotic component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (opioid receptor antagonist class)

Paion UK Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). A. CNS 7056 — Competitive Intelligence Brief. https://druglandscape.com/ci/a-cns-7056. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab